Janux Therapeutics (JANX) Cash & Equivalents (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Cash & Equivalents of $51.8 million for Q1 2026, down 29.72% year-over-year from $73.7 million in Q1 2025, and down 0.97% quarter-over-quarter from $52.3 million in Q4 2025.
Janux Therapeutics (JANX) Cash & Equivalents (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Cash & Equivalents for 7 consecutive years, with $51.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 29.72% year-over-year to $51.8 million; the TTM figure through Mar 2026 stood at $51.8 million (down 29.72% YoY), while the FY2025 annual figure was $52.3 million, down 87.85% from the prior year.
- Cash & Equivalents slipped to $51.8 million in Q1 2026 per JANX's latest filing, from $52.3 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $430.6 million in Q4 2024 and bottomed at $14.7 million in Q2 2024.
- Historically, Cash & Equivalents has averaged $76.1 million across 5 years, with a median of $51.8 million in 2026.
- Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 2142.15% — and 2025, when it tumbled 87.85%.
- Janux Therapeutics' Cash & Equivalents stood at $51.4 million in 2022, then plunged by 62.66% to $19.2 million in 2023, then surged by 2142.15% to $430.6 million in 2024, then sank by 87.85% to $52.3 million in 2025, then retreated by 0.97% to $51.8 million in 2026.
- Business Quant data shows JANX's Cash & Equivalents at $51.8 million in Q1 2026, $52.3 million in Q4 2025, and $48.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 27.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.77 Mn |
| Mar 31, 2026 | 51.83 Mn |
| Dec 31, 2025 | 52.33 Mn |
| Sep 30, 2025 | 48.39 Mn |
| Jun 30, 2025 | 52.45 Mn |
| Mar 31, 2025 | 73.74 Mn |
| Dec 31, 2024 | 430.61 Mn |
| Sep 30, 2024 | 26.75 Mn |
| Jun 30, 2024 | 14.66 Mn |
| Mar 31, 2024 | 212.80 Mn |
| Dec 31, 2023 | 19.21 Mn |
| Sep 30, 2023 | 17.15 Mn |
| Jun 30, 2023 | 33.70 Mn |
| Mar 31, 2023 | 30.36 Mn |
| Dec 31, 2022 | 51.43 Mn |
| Sep 30, 2022 | 64.75 Mn |
| Jun 30, 2022 | 58.40 Mn |
| Mar 31, 2022 | 55.13 Mn |
| Dec 31, 2021 | 35.58 Mn |
| Sep 30, 2021 | 39.39 Mn |